Mesoblast Ltd ADR MESO

Morningstar Rating
$11.18 −0.46 (3.95%)
View Full Chart

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

MESO is trading at a LOCK|l%cl premium.
Price
$11.20
Fair Value
LOCK|.P$>W@$P
Uncertainty
LOCK|>^ R&VW
1-Star Price
LOCK|.M@>ryQD
5-Star Price
LOCK|.wczJf>
Economic Moat
LOCK|#C
Capital Allocation
—

News

Trading Information

Previous Close Price
$11.64
Day Range
$11.02–11.56
52-Week Range
$11.02–21.50
Bid/Ask
$4.50 / $15.01
Shares Outstanding
129.85M
Market Cap
$1.45B
Volume/Avg
262,559 / 239,596

Key Statistics

Price/Earnings (Normalized)
—
Price/Sales
12.53
Dividend Yield (Trailing)
0.00%
Dividend Yield (Forward)
0.00%
Dividend Payment Schedule
—
Total Yield
—

Company Profile

Mesoblast Ltd is a commercial-stage biotechnology company engaged in developing and commercializing allogeneic (off-the-shelf) cellular medicines for severe inflammatory conditions. Its commercial product, Ryoncil (remestemcel-L-rknd), is FDA-approved for steroid-refractory acute graft-versus-host disease in pediatric patients. The company is also developing Ryoncil for additional inflammatory indications. Its rexlemestrocel-L platform is being developed for chronic low back pain associated with degenerative disc disease and chronic heart failure. The company operates as a single segment focused on its allogeneic cellular medicines platform.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Mid Growth
Total Number of Employees
108

Valuation

Metric
MESO
Price/Earnings (Normalized)
—
Price/Book Value
2.66
Price/Sales
12.53
Price/Cash Flow
—
Price/Earnings
MESO

Financial Strength

Metric
MESO
Quick Ratio
1.30
Current Ratio
2.43
Interest Coverage
—
Quick Ratio
MESO

Profitability

Metric
MESO
Return on Assets (Normalized)
—
Return on Equity (Normalized)
—
Return on Invested Capital (Normalized)
—
Return on Assets
MESO

Biotechnology Industry Comparables

1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Vertex Pharmaceuticals Inc
VRTX
LOCK|L%#!V@bLOCK|PV<f%$132B
Regeneron Pharmaceuticals Inc
REGN
LOCK|n^Fgs>LOCK|>FM%Z$96B
Moderna Inc
MRNA
LOCK|WnzcgdLOCK|<s$81B
argenx SE ADR
ARGX
LOCK|W>&KvDLOCK|>R$59B
BeOne Medicines Ltd ADR
ONC
LOCK|Xp?>^sLOCK|l&k$47B
Royalty Pharma PLC Class A
RPRX
LOCK|yNhj>c$LOCK|G!V#$30B
Incyte Corp
INCY
LOCK|!s$n%CLOCK|R>$24B
BioNTech SE ADR
BNTX
LOCK|HdZwsl$LOCK|X$L$20B
Alnylam Pharmaceuticals Inc
ALNY
LOCK|tYFbFDLOCK|$W@pK$20B
BridgeBio Pharma Inc
BBIO
LOCK|?B<>g?HLOCK|S!$15B

Sponsor Center